Biologics

The global spine biologics market is expected to reach $2.7 billion by 2024, increasing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.

Judge Brouck Jacobs ordered the Columbia-based University of Missouri to comply with a discovery request of its biojoint surgery records, according to the Columbia Tribune.

Japan approved Stemirac, a stem cell treatment for spinal cord injuries, Nature reports.

Asterias Biotherapeutics conducted a clinical trial to study the effectiveness of its OPC1 cells, Seeking Alpha reports. The company released its one-year results.

The American Association of Hip and Knee Surgeons does not currently recommend biologic treatments for advanced hip or knee arthritis, according to a new position statement.

Broomfield, Colo.-based Centeno-Schultz Clinic's Christopher J. Centeno, MD, is urging Colorado legislators to crackdown on unregulated stem cell treatments, The Denver Channel reports.

Rancho Mirage, Calif.-based Star Ortho is now offering Lipogems as an alternative or supplement to orthopedic surgery.

The global biomaterials market is predicted to reach more than $173 billion by 2022, growing at a 16 percent compound annual growth rate, according to a Market Research Engine report.

More and more surgeons are beginning to talk about biologics, stem cells and regenerative medicine. Sameer Mathur, MD, an orthopedic surgeon, explains the future of stem cells in a sponsored article with WRAL.com.

Bert Mandelbaum, MD, described the evidence supporting orthobiologic treatments for torn anterior cruciate ligaments in a Medscape column.